Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The user maintained hair with finasteride for 4.5 years and noticed some progress with dutasteride after 6 months, experiencing reduced chest and facial hair. They did not use minoxidil and reported no side effects from either treatment.

The conversation discusses updates on hair loss treatments, specifically GT20029, PP405, and a rumored injectable peptide from UT. GT20029 is seen as a promising treatment expected within 5-7 years.

The user switched from finasteride to dutasteride and oral minoxidil after experiencing side effects and worsening hair loss, which improved their condition. Dutasteride was preferred due to fewer side effects and better results compared to finasteride.

A user shared their 4-year progress using topical minoxidil and 1mg finasteride daily for hair regrowth, noting plans to reduce finasteride due to minor side effects. They emphasized consistency as key to success, with noticeable improvements in hair density and color.

The conversation is about a 29-year-old's 4-month progress using topical dutasteride and minoxidil for hair loss. Users inquire about the specific products, dosage, and any side effects.

Verteporfin, used with dermal incisions by doctors like Dr. Melissa Toyos, is suggested as a promising treatment for high Norwood hair loss, with some users reporting significant regrowth. However, there is skepticism about its effectiveness due to concurrent use of other treatments like dutasteride and oral minoxidil.

GT20029 is an experimental topical treatment for male-pattern hair loss, showing promising results in Phase 2 trials and moving towards Phase 3. It aims to degrade androgen receptors in hair follicles, differing from treatments like finasteride and minoxidil.

PP405 trials have completed phase 2a, showing promising results with a 31% stat for hair density increase, and are moving directly to phase 3. Detailed results will be presented at a medical conference in 2026.

A 26-year-old male with high testosterone is experiencing diffuse hair thinning despite using a comprehensive treatment regimen including dutasteride, oral minoxidil, RU58841, ketoconazole shampoo, microneedling, and low-level laser therapy. Suggestions include adjusting dutasteride dosage, monitoring iron levels, and consulting a dermatologist for further evaluation.

The user switched from finasteride to dutasteride and is seeking feedback on hair changes after 4 months. The current regimen includes oral dutasteride, oral minoxidil, and topical minoxidil.

GT20029 and KX826 are promising hair loss treatments, with GT20029 increasing hair count and KX826 showing significant results. KX826 may be a good alternative for those who can't use finasteride or dutasteride, though results vary.

Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.

A 35-year-old shared a 4-month update on their hair transplant of 3,153 grafts in Turkey, noting redness and uneven growth but hoping for improved density. They have been using finasteride for over 13 years and are optimistic about future results.

A user shared their 4-month progress using 1mg finasteride and minoxidil foam once a day for hair loss. Another user complimented the results and asked about their age.

A 38-year-old man shared his 4-month hair loss progress using finasteride, oral minoxidil, and supplements like zinc and DIM. He experienced positive results without major shedding and managed side effects with DIM.

The conversation humorously discusses the effects of finasteride on sexual orientation and hair improvement, with users joking about its potential to change attraction. It also mentions other treatments like dutasteride and minoxidil, with some users sharing their experiences and side effects.

User shared 4-month progress on hair loss treatment using 0.25mg finasteride daily and topical minoxidil daily, noting cognitive decline possibly linked to finasteride. Users discussed side effects, alternative treatments, and shared similar experiences.

A new topical treatment, PP405, shows promising results for hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil. However, it may still need to be combined with DHT blockers for optimal results, and its long-term effectiveness remains uncertain.

A 33-year-old male shared his 4-month hair growth progress using 1mg finasteride and 2.5mg minoxidil daily, along with hair supplements and a serum containing Redensyl, Anagain, Capixyl, and Procapil. He reported thickening of existing hair and new hair growth without side effects.

A user shared progress pictures showing improvement from NW6 diffuse to NW1 after 5 months of finasteride and 2 months of dutasteride. Another user asked if these treatments affected beard or body hair thickness.

PP405 is ineffective for miniaturized, fibrosed hair follicles in androgenetic alopecia. AMP303 may activate hair follicle stem cells, but minoxidil and finasteride are still the main treatments.

Ritlecitinib and PP405 show promise for hair regrowth. Diagnosing the cause of hair loss is crucial before treatment.

A 19-year-old reports positive hair regrowth using oral minoxidil and finasteride, with no side effects. The conversation includes advice on consulting a dermatologist and exploring alternative treatments.

OP used finasteride, topical minoxidil, microneedling, and caffeine shampoo for hair loss. After 4 months, they saw progress with new, lighter-colored hairs.

The conversation is about hair regrowth using finasteride and minoxidil, with users noting visible new hair growth and discussing dosages. Some users express encouragement and hope, while one advises against using finasteride.

Finasteride is effective for DHT/AR-driven hair loss but not for chromosome 20-driven cases, where treatments like minoxidil, prostaglandin analogs, and low-level laser therapy may be more beneficial. Genetic testing can help determine the underlying cause of hair loss to tailor treatment effectively.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

The user shared their 4-month progress using oral finasteride and topical minoxidil, with a specific application routine. They adjust the minoxidil application to manage costs, applying it daily with variations in quantity and additional tretinoin on certain days.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

The user reported significant hair regrowth after 4 months using Dutasteride, oral and topical Minoxidil, Nizoral shampoo, and dermastamping. They experienced minor side effects but noted consistent progress and regrowth, especially at the hairline and temples.